Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asciminib - Novartis

Next Previous
Drug Profile

Asciminib - Novartis

Alternative Names: ABL 001; ABL-001 - Novartis; Asciminib hydrochloride - Novartis; Scemblix; Scemblix asciminib; STAMP inhibitor - Novartis

Latest Information Update: 11 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Pharmaceuticals Corporation
  • Class Amides; Antineoplastics; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Phenyl ethers; Pyrazoles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • No development reported Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 04 Feb 2026 Novartis plans a phase I/II trial for Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, Second-line therapy or greater, In children, In adults, In adolescents, In infants) (PO), in March 2026 , (CTIS2025-522019-40) (NCT07387926)
  • 04 Feb 2026 Registered for Chronic myeloid leukaemia (First-line therapy) in Iceland, Liechtenstein, European Union, Norway (PO)
  • 21 Jan 2026 Novartis Pharmaceuticals plans a phase II trial for Chronic myeloid leukemia (In children, In infants, In adolescents) in June 2026 (PO, Tablet) (NCT07354074)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top